MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: A study of 90 tumors

Predicting tumor behavior in meningiomas based on histology alone has been problematic. This study retrospectively compares histology and MIB-1 (cell proliferation marker) labeling indices (LI) in benign, aggressive, and malignant meningiomas. Six histological features, including mitoses, necrosis,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Human pathology 1998-12, Vol.29 (12), p.1420-1427
Hauptverfasser: Abramovich, Caroline M, Prayson, Richard A
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1427
container_issue 12
container_start_page 1420
container_title Human pathology
container_volume 29
creator Abramovich, Caroline M
Prayson, Richard A
description Predicting tumor behavior in meningiomas based on histology alone has been problematic. This study retrospectively compares histology and MIB-1 (cell proliferation marker) labeling indices (LI) in benign, aggressive, and malignant meningiomas. Six histological features, including mitoses, necrosis, loss of pattern, hypervascularity/ hemosiderin deposition, prominent nucleoli, and nuclear pleomorphism, were compared in 90 meningiomas (Fisher's exact test). Tumors with two or more of the above features were designated as aggressive meningiomas. Malignant meningiomas were characterized by brain invasion or metastasis. The MIB-1 Us (% positive tumor cell nuclei) were compared between the three groups (Kruskal-Wallis test, Wilcoxon two-sample test). Of the benign meningiomas ( n = 37; mean age, 54 years), 41% had one of the six histological features, with nuclear pleomorphism ( n = 10) being the most frequent. The aggressive tumors ( n = 29; mean age, 61 years) were characterized by nuclear pleomorphism ( n = 28), mitoses ( n = 20), necrosis ( n = 16), loss of pattern ( n = 16), prominent nucleoli ( n = 6), and hypervascularity/hemosiderin deposition ( n = 5). Malignant tumors ( n = 24; mean age, 59 years) were characterized by nuclear pleomorphism ( n = 22), mitoses ( n = 21), loss of pattern ( n = 21), necrosis ( n = 21), nucleoli ( n = 17), and hypervascularity/hemosiderin deposition ( n = 3). Significant differences were found between the aggressive and malignant groups with regard to loss of pattern, necrosis, and nucleoli ( P = .0043, .011, and .00029, respectively). Mean MIB-1 LIs for the benign, aggressive, and malignant groups were 1.0% (range, 0 to 5.5%), 5.5% (range, 0.1 to 32.5%), and 12.0% (range, 0.3 to 32.5%), respectively. Differences in the mean MIB-1 LI between groups were statistically significant, with P values of
doi_str_mv 10.1016/S0046-8177(98)90010-7
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69103557</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0046817798900107</els_id><sourcerecordid>69103557</sourcerecordid><originalsourceid>FETCH-LOGICAL-c389t-5d175bcdc32e2c8aa20f408427dcb8d1091303dcac2b28ef2145a572bc655b5c3</originalsourceid><addsrcrecordid>eNqFkFuL1TAQgIMo63H1JyzkQUTBapI2beKLrIuXhRUf1EcJ6WRaIm26ZtqF_ffm7Dmsjz7NMPPNhY-xMyneSCHbt9-FaNrKyK57ac0rK4QUVfeA7aSuVWVqqx6y3T3ymD0h-l0YqRt9wk6sabVR3Y79-nr5oZJ88j1OMY08phABqUTeY4pjes39OGYkijdY8hT47KdS92nlcyHSGJfZ0zt-zmndwi1fBm4FX7d5yfSUPRr8RPjsGE_Zz08ff1x8qa6-fb68OL-qoDZ2rXSQne4hQK1QgfFeiaERplFdgN4EKaysRR3Ag-qVwUHJRnvdqR5arXsN9Sl7cdh7nZc_G9Lq5kiA0-QTLhu51kpRa90VUB9AyAtRxsFd5zj7fOukcHut7k6r2ztz1rg7rW4_d3Y8sPUzhvupo8fSf37sewI_DdkniPRvedsIa1XB3h8wLDJuImZHEDEBhpgRVheW-J9H_gI0npLx</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69103557</pqid></control><display><type>article</type><title>MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: A study of 90 tumors</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Abramovich, Caroline M ; Prayson, Richard A</creator><creatorcontrib>Abramovich, Caroline M ; Prayson, Richard A</creatorcontrib><description>Predicting tumor behavior in meningiomas based on histology alone has been problematic. This study retrospectively compares histology and MIB-1 (cell proliferation marker) labeling indices (LI) in benign, aggressive, and malignant meningiomas. Six histological features, including mitoses, necrosis, loss of pattern, hypervascularity/ hemosiderin deposition, prominent nucleoli, and nuclear pleomorphism, were compared in 90 meningiomas (Fisher's exact test). Tumors with two or more of the above features were designated as aggressive meningiomas. Malignant meningiomas were characterized by brain invasion or metastasis. The MIB-1 Us (% positive tumor cell nuclei) were compared between the three groups (Kruskal-Wallis test, Wilcoxon two-sample test). Of the benign meningiomas ( n = 37; mean age, 54 years), 41% had one of the six histological features, with nuclear pleomorphism ( n = 10) being the most frequent. The aggressive tumors ( n = 29; mean age, 61 years) were characterized by nuclear pleomorphism ( n = 28), mitoses ( n = 20), necrosis ( n = 16), loss of pattern ( n = 16), prominent nucleoli ( n = 6), and hypervascularity/hemosiderin deposition ( n = 5). Malignant tumors ( n = 24; mean age, 59 years) were characterized by nuclear pleomorphism ( n = 22), mitoses ( n = 21), loss of pattern ( n = 21), necrosis ( n = 21), nucleoli ( n = 17), and hypervascularity/hemosiderin deposition ( n = 3). Significant differences were found between the aggressive and malignant groups with regard to loss of pattern, necrosis, and nucleoli ( P = .0043, .011, and .00029, respectively). Mean MIB-1 LIs for the benign, aggressive, and malignant groups were 1.0% (range, 0 to 5.5%), 5.5% (range, 0.1 to 32.5%), and 12.0% (range, 0.3 to 32.5%), respectively. Differences in the mean MIB-1 LI between groups were statistically significant, with P values of &lt;.0001 (benign v aggressive) and .0012 (aggressive v malignant). Mean MIB-1 LIs for recurrent versus nonrecurrent tumors were 7.1% (range, 0 to 32.5%) versus 3.8% (range, 0 to 20.9%) ( P = .32). The mean MIB-1 LI for patients who were alive with or without tumor was 6.2% (range, 0 to 32.5%) versus a mean MIB-1 LI of 14.2% (range, 2.8% to 32.5%) for patients who died of or with tumor ( P = .0013). In conclusion, (1) There is a statistically significant difference in the increasing MIB-1 LI means between benign, aggressive, and malignant meningiomas and between patients who were alive versus those who died; (2) there is some overlap in MIB-1 LI ranges between groups, which warrants caution in interpreting an individual MIB-1 LI in a given tumor.</description><identifier>ISSN: 0046-8177</identifier><identifier>EISSN: 1532-8392</identifier><identifier>DOI: 10.1016/S0046-8177(98)90010-7</identifier><identifier>PMID: 9865827</identifier><identifier>CODEN: HPCQA4</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; aggressive meningioma ; Antigens, Nuclear ; atypical meningioma ; Biological and medical sciences ; Biomarkers ; Female ; Humans ; Immunoenzyme Techniques ; Ki-67 Antigen ; Male ; malignant meningioma ; Medical sciences ; Meningeal Neoplasms - metabolism ; Meningeal Neoplasms - mortality ; Meningeal Neoplasms - pathology ; meningioma ; Meningioma - metabolism ; Meningioma - mortality ; Meningioma - pathology ; MIB-1 antibody ; Middle Aged ; Mitotic Index ; Neoplasm Invasiveness - pathology ; Neoplasm Recurrence, Local - pathology ; Neurology ; Nuclear Proteins - metabolism ; Retrospective Studies ; Survival Analysis ; Tumors of the nervous system. Phacomatoses</subject><ispartof>Human pathology, 1998-12, Vol.29 (12), p.1420-1427</ispartof><rights>1998</rights><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c389t-5d175bcdc32e2c8aa20f408427dcb8d1091303dcac2b28ef2145a572bc655b5c3</citedby><cites>FETCH-LOGICAL-c389t-5d175bcdc32e2c8aa20f408427dcb8d1091303dcac2b28ef2145a572bc655b5c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0046817798900107$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>309,310,314,776,780,785,786,3537,23909,23910,25118,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1640992$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9865827$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abramovich, Caroline M</creatorcontrib><creatorcontrib>Prayson, Richard A</creatorcontrib><title>MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: A study of 90 tumors</title><title>Human pathology</title><addtitle>Hum Pathol</addtitle><description>Predicting tumor behavior in meningiomas based on histology alone has been problematic. This study retrospectively compares histology and MIB-1 (cell proliferation marker) labeling indices (LI) in benign, aggressive, and malignant meningiomas. Six histological features, including mitoses, necrosis, loss of pattern, hypervascularity/ hemosiderin deposition, prominent nucleoli, and nuclear pleomorphism, were compared in 90 meningiomas (Fisher's exact test). Tumors with two or more of the above features were designated as aggressive meningiomas. Malignant meningiomas were characterized by brain invasion or metastasis. The MIB-1 Us (% positive tumor cell nuclei) were compared between the three groups (Kruskal-Wallis test, Wilcoxon two-sample test). Of the benign meningiomas ( n = 37; mean age, 54 years), 41% had one of the six histological features, with nuclear pleomorphism ( n = 10) being the most frequent. The aggressive tumors ( n = 29; mean age, 61 years) were characterized by nuclear pleomorphism ( n = 28), mitoses ( n = 20), necrosis ( n = 16), loss of pattern ( n = 16), prominent nucleoli ( n = 6), and hypervascularity/hemosiderin deposition ( n = 5). Malignant tumors ( n = 24; mean age, 59 years) were characterized by nuclear pleomorphism ( n = 22), mitoses ( n = 21), loss of pattern ( n = 21), necrosis ( n = 21), nucleoli ( n = 17), and hypervascularity/hemosiderin deposition ( n = 3). Significant differences were found between the aggressive and malignant groups with regard to loss of pattern, necrosis, and nucleoli ( P = .0043, .011, and .00029, respectively). Mean MIB-1 LIs for the benign, aggressive, and malignant groups were 1.0% (range, 0 to 5.5%), 5.5% (range, 0.1 to 32.5%), and 12.0% (range, 0.3 to 32.5%), respectively. Differences in the mean MIB-1 LI between groups were statistically significant, with P values of &lt;.0001 (benign v aggressive) and .0012 (aggressive v malignant). Mean MIB-1 LIs for recurrent versus nonrecurrent tumors were 7.1% (range, 0 to 32.5%) versus 3.8% (range, 0 to 20.9%) ( P = .32). The mean MIB-1 LI for patients who were alive with or without tumor was 6.2% (range, 0 to 32.5%) versus a mean MIB-1 LI of 14.2% (range, 2.8% to 32.5%) for patients who died of or with tumor ( P = .0013). In conclusion, (1) There is a statistically significant difference in the increasing MIB-1 LI means between benign, aggressive, and malignant meningiomas and between patients who were alive versus those who died; (2) there is some overlap in MIB-1 LI ranges between groups, which warrants caution in interpreting an individual MIB-1 LI in a given tumor.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>aggressive meningioma</subject><subject>Antigens, Nuclear</subject><subject>atypical meningioma</subject><subject>Biological and medical sciences</subject><subject>Biomarkers</subject><subject>Female</subject><subject>Humans</subject><subject>Immunoenzyme Techniques</subject><subject>Ki-67 Antigen</subject><subject>Male</subject><subject>malignant meningioma</subject><subject>Medical sciences</subject><subject>Meningeal Neoplasms - metabolism</subject><subject>Meningeal Neoplasms - mortality</subject><subject>Meningeal Neoplasms - pathology</subject><subject>meningioma</subject><subject>Meningioma - metabolism</subject><subject>Meningioma - mortality</subject><subject>Meningioma - pathology</subject><subject>MIB-1 antibody</subject><subject>Middle Aged</subject><subject>Mitotic Index</subject><subject>Neoplasm Invasiveness - pathology</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Neurology</subject><subject>Nuclear Proteins - metabolism</subject><subject>Retrospective Studies</subject><subject>Survival Analysis</subject><subject>Tumors of the nervous system. Phacomatoses</subject><issn>0046-8177</issn><issn>1532-8392</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkFuL1TAQgIMo63H1JyzkQUTBapI2beKLrIuXhRUf1EcJ6WRaIm26ZtqF_ffm7Dmsjz7NMPPNhY-xMyneSCHbt9-FaNrKyK57ac0rK4QUVfeA7aSuVWVqqx6y3T3ymD0h-l0YqRt9wk6sabVR3Y79-nr5oZJ88j1OMY08phABqUTeY4pjes39OGYkijdY8hT47KdS92nlcyHSGJfZ0zt-zmndwi1fBm4FX7d5yfSUPRr8RPjsGE_Zz08ff1x8qa6-fb68OL-qoDZ2rXSQne4hQK1QgfFeiaERplFdgN4EKaysRR3Ag-qVwUHJRnvdqR5arXsN9Sl7cdh7nZc_G9Lq5kiA0-QTLhu51kpRa90VUB9AyAtRxsFd5zj7fOukcHut7k6r2ztz1rg7rW4_d3Y8sPUzhvupo8fSf37sewI_DdkniPRvedsIa1XB3h8wLDJuImZHEDEBhpgRVheW-J9H_gI0npLx</recordid><startdate>19981201</startdate><enddate>19981201</enddate><creator>Abramovich, Caroline M</creator><creator>Prayson, Richard A</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19981201</creationdate><title>MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: A study of 90 tumors</title><author>Abramovich, Caroline M ; Prayson, Richard A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c389t-5d175bcdc32e2c8aa20f408427dcb8d1091303dcac2b28ef2145a572bc655b5c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>aggressive meningioma</topic><topic>Antigens, Nuclear</topic><topic>atypical meningioma</topic><topic>Biological and medical sciences</topic><topic>Biomarkers</topic><topic>Female</topic><topic>Humans</topic><topic>Immunoenzyme Techniques</topic><topic>Ki-67 Antigen</topic><topic>Male</topic><topic>malignant meningioma</topic><topic>Medical sciences</topic><topic>Meningeal Neoplasms - metabolism</topic><topic>Meningeal Neoplasms - mortality</topic><topic>Meningeal Neoplasms - pathology</topic><topic>meningioma</topic><topic>Meningioma - metabolism</topic><topic>Meningioma - mortality</topic><topic>Meningioma - pathology</topic><topic>MIB-1 antibody</topic><topic>Middle Aged</topic><topic>Mitotic Index</topic><topic>Neoplasm Invasiveness - pathology</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Neurology</topic><topic>Nuclear Proteins - metabolism</topic><topic>Retrospective Studies</topic><topic>Survival Analysis</topic><topic>Tumors of the nervous system. Phacomatoses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abramovich, Caroline M</creatorcontrib><creatorcontrib>Prayson, Richard A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Human pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abramovich, Caroline M</au><au>Prayson, Richard A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: A study of 90 tumors</atitle><jtitle>Human pathology</jtitle><addtitle>Hum Pathol</addtitle><date>1998-12-01</date><risdate>1998</risdate><volume>29</volume><issue>12</issue><spage>1420</spage><epage>1427</epage><pages>1420-1427</pages><issn>0046-8177</issn><eissn>1532-8392</eissn><coden>HPCQA4</coden><abstract>Predicting tumor behavior in meningiomas based on histology alone has been problematic. This study retrospectively compares histology and MIB-1 (cell proliferation marker) labeling indices (LI) in benign, aggressive, and malignant meningiomas. Six histological features, including mitoses, necrosis, loss of pattern, hypervascularity/ hemosiderin deposition, prominent nucleoli, and nuclear pleomorphism, were compared in 90 meningiomas (Fisher's exact test). Tumors with two or more of the above features were designated as aggressive meningiomas. Malignant meningiomas were characterized by brain invasion or metastasis. The MIB-1 Us (% positive tumor cell nuclei) were compared between the three groups (Kruskal-Wallis test, Wilcoxon two-sample test). Of the benign meningiomas ( n = 37; mean age, 54 years), 41% had one of the six histological features, with nuclear pleomorphism ( n = 10) being the most frequent. The aggressive tumors ( n = 29; mean age, 61 years) were characterized by nuclear pleomorphism ( n = 28), mitoses ( n = 20), necrosis ( n = 16), loss of pattern ( n = 16), prominent nucleoli ( n = 6), and hypervascularity/hemosiderin deposition ( n = 5). Malignant tumors ( n = 24; mean age, 59 years) were characterized by nuclear pleomorphism ( n = 22), mitoses ( n = 21), loss of pattern ( n = 21), necrosis ( n = 21), nucleoli ( n = 17), and hypervascularity/hemosiderin deposition ( n = 3). Significant differences were found between the aggressive and malignant groups with regard to loss of pattern, necrosis, and nucleoli ( P = .0043, .011, and .00029, respectively). Mean MIB-1 LIs for the benign, aggressive, and malignant groups were 1.0% (range, 0 to 5.5%), 5.5% (range, 0.1 to 32.5%), and 12.0% (range, 0.3 to 32.5%), respectively. Differences in the mean MIB-1 LI between groups were statistically significant, with P values of &lt;.0001 (benign v aggressive) and .0012 (aggressive v malignant). Mean MIB-1 LIs for recurrent versus nonrecurrent tumors were 7.1% (range, 0 to 32.5%) versus 3.8% (range, 0 to 20.9%) ( P = .32). The mean MIB-1 LI for patients who were alive with or without tumor was 6.2% (range, 0 to 32.5%) versus a mean MIB-1 LI of 14.2% (range, 2.8% to 32.5%) for patients who died of or with tumor ( P = .0013). In conclusion, (1) There is a statistically significant difference in the increasing MIB-1 LI means between benign, aggressive, and malignant meningiomas and between patients who were alive versus those who died; (2) there is some overlap in MIB-1 LI ranges between groups, which warrants caution in interpreting an individual MIB-1 LI in a given tumor.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>9865827</pmid><doi>10.1016/S0046-8177(98)90010-7</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0046-8177
ispartof Human pathology, 1998-12, Vol.29 (12), p.1420-1427
issn 0046-8177
1532-8392
language eng
recordid cdi_proquest_miscellaneous_69103557
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Adolescent
Adult
Aged
Aged, 80 and over
aggressive meningioma
Antigens, Nuclear
atypical meningioma
Biological and medical sciences
Biomarkers
Female
Humans
Immunoenzyme Techniques
Ki-67 Antigen
Male
malignant meningioma
Medical sciences
Meningeal Neoplasms - metabolism
Meningeal Neoplasms - mortality
Meningeal Neoplasms - pathology
meningioma
Meningioma - metabolism
Meningioma - mortality
Meningioma - pathology
MIB-1 antibody
Middle Aged
Mitotic Index
Neoplasm Invasiveness - pathology
Neoplasm Recurrence, Local - pathology
Neurology
Nuclear Proteins - metabolism
Retrospective Studies
Survival Analysis
Tumors of the nervous system. Phacomatoses
title MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: A study of 90 tumors
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T19%3A14%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MIB-1%20labeling%20indices%20in%20benign,%20aggressive,%20and%20malignant%20meningiomas:%20A%20study%20of%2090%20tumors&rft.jtitle=Human%20pathology&rft.au=Abramovich,%20Caroline%20M&rft.date=1998-12-01&rft.volume=29&rft.issue=12&rft.spage=1420&rft.epage=1427&rft.pages=1420-1427&rft.issn=0046-8177&rft.eissn=1532-8392&rft.coden=HPCQA4&rft_id=info:doi/10.1016/S0046-8177(98)90010-7&rft_dat=%3Cproquest_cross%3E69103557%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69103557&rft_id=info:pmid/9865827&rft_els_id=S0046817798900107&rfr_iscdi=true